Syntax Research’s Regeneron Pharmaceuticals REGN Stock Holding History

Syntax Research’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153K	Hold	245	–	–	0.11%	64
2026 Q1	$189K	Hold	245	–	–	0.12%	67
2025 Q4	$189K	Hold	245	–	–	0.12%	66
2025 Q3	$138K	Hold	245	–	–	0.09%	73
2025 Q2	$129K	Hold	245	–	–	0.09%	68
2025 Q1	$155K	Hold	245	–	–	0.11%	70
2024 Q4	$175K	Hold	245	–	–	0.13%	65
2024 Q3	$258K	Sell	245 -100	-29%	-$111K	0.17%	58
2024 Q2	$363K	Hold	345	–	–	0.29%	46
2024 Q1	$332K	Hold	345	–	–	0.25%	52
2023 Q4	$303K	Hold	345	–	–	0.25%	51
2023 Q3	$284K	Buy	+345	New	+$271K	0.23%	53

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Syntax Research's REGN Position: Q2 2026 in Review

Syntax Research held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 245 shares worth $153K. The position accounts for 0.11% of the portfolio, ranked #64.

Syntax Research first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $363K in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Syntax Research held 245 shares of Regeneron Pharmaceuticals worth $153K as of Q2 2026.
Syntax Research left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.11% of Syntax Research's portfolio in Q2 2026, its #64 holding.
Syntax Research first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Syntax Research's Regeneron Pharmaceuticals position peaked at $363K in Q2 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Syntax Research's 13F filing for Q2 2026, filed 31 Jul 2026.